DE60020994T2 - Neue verwendung sowie neue n-azabicycloamid-verbindungen - Google Patents
Neue verwendung sowie neue n-azabicycloamid-verbindungen Download PDFInfo
- Publication number
- DE60020994T2 DE60020994T2 DE60020994T DE60020994T DE60020994T2 DE 60020994 T2 DE60020994 T2 DE 60020994T2 DE 60020994 T DE60020994 T DE 60020994T DE 60020994 T DE60020994 T DE 60020994T DE 60020994 T2 DE60020994 T2 DE 60020994T2
- Authority
- DE
- Germany
- Prior art keywords
- oct
- azabicyclo
- propenamide
- compound
- phenylpropenamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 title claims description 141
- -1 -CO 2 R 7 Chemical group 0.000 claims description 72
- 239000001257 hydrogen Substances 0.000 claims description 41
- 229910052739 hydrogen Inorganic materials 0.000 claims description 41
- 150000003839 salts Chemical class 0.000 claims description 36
- 238000011282 treatment Methods 0.000 claims description 30
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 24
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 22
- 229910052717 sulfur Inorganic materials 0.000 claims description 22
- 125000003118 aryl group Chemical group 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 229910052736 halogen Inorganic materials 0.000 claims description 17
- 150000002367 halogens Chemical class 0.000 claims description 17
- 229910052760 oxygen Inorganic materials 0.000 claims description 17
- 150000002431 hydrogen Chemical class 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 14
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 14
- 125000004434 sulfur atom Chemical group 0.000 claims description 14
- 208000024827 Alzheimer disease Diseases 0.000 claims description 13
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 13
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 13
- 239000001301 oxygen Substances 0.000 claims description 13
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 12
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 12
- 125000001072 heteroaryl group Chemical group 0.000 claims description 12
- 208000019901 Anxiety disease Diseases 0.000 claims description 10
- 208000002193 Pain Diseases 0.000 claims description 10
- 208000018737 Parkinson disease Diseases 0.000 claims description 10
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 10
- 208000016620 Tourette disease Diseases 0.000 claims description 10
- 230000036506 anxiety Effects 0.000 claims description 10
- 201000000980 schizophrenia Diseases 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 10
- APEJMQOBVMLION-VOTSOKGWSA-N trans-cinnamamide Chemical compound NC(=O)\C=C\C1=CC=CC=C1 APEJMQOBVMLION-VOTSOKGWSA-N 0.000 claims description 10
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 9
- 208000000044 Amnesia Diseases 0.000 claims description 9
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 9
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 9
- 208000020925 Bipolar disease Diseases 0.000 claims description 9
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims description 9
- 208000023105 Huntington disease Diseases 0.000 claims description 9
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims description 9
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 9
- 201000002832 Lewy body dementia Diseases 0.000 claims description 9
- 206010026749 Mania Diseases 0.000 claims description 9
- 206010057852 Nicotine dependence Diseases 0.000 claims description 9
- 208000028017 Psychotic disease Diseases 0.000 claims description 9
- 208000025569 Tobacco Use disease Diseases 0.000 claims description 9
- 208000028683 bipolar I disease Diseases 0.000 claims description 9
- 230000001713 cholinergic effect Effects 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 9
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims description 9
- 201000003723 learning disability Diseases 0.000 claims description 9
- 229960002715 nicotine Drugs 0.000 claims description 9
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 9
- 230000036407 pain Effects 0.000 claims description 9
- 210000000225 synapse Anatomy 0.000 claims description 9
- MENCFQRKJSFDJH-AATRIKPKSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(2-nitrophenyl)prop-2-enamide Chemical compound [O-][N+](=O)C1=CC=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 MENCFQRKJSFDJH-AATRIKPKSA-N 0.000 claims description 8
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 8
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- ODFSOOCVJPIZNA-VOTSOKGWSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-phenylprop-2-enamide Chemical compound C1N(CC2)CCC2C1NC(=O)\C=C\C1=CC=CC=C1 ODFSOOCVJPIZNA-VOTSOKGWSA-N 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 230000005586 smoking cessation Effects 0.000 claims description 7
- PHZYWNWABJJERF-AATRIKPKSA-N (e)-3-(2-aminophenyl)-n-(1-azabicyclo[2.2.2]octan-3-yl)prop-2-enamide Chemical compound NC1=CC=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 PHZYWNWABJJERF-AATRIKPKSA-N 0.000 claims description 6
- RCLFFPCOTKNDRK-VFQAQYNWSA-N (e)-3-(4-aminophenyl)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]prop-2-enamide Chemical compound C1=CC(N)=CC=C1\C=C\C(=O)N[C@@H]1C(CC2)CCN2C1 RCLFFPCOTKNDRK-VFQAQYNWSA-N 0.000 claims description 6
- QLXOOYGFEACOIW-BQYQJAHWSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-n-methyl-3-phenylprop-2-enamide Chemical compound C1N(CC2)CCC2C1N(C)C(=O)\C=C\C1=CC=CC=C1 QLXOOYGFEACOIW-BQYQJAHWSA-N 0.000 claims description 6
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 230000004770 neurodegeneration Effects 0.000 claims description 6
- UCRCSZYDUAPEEU-SNAWJCMRSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(3-iodophenyl)prop-2-enamide Chemical compound IC1=CC=CC(\C=C\C(=O)NC2C3CCN(CC3)C2)=C1 UCRCSZYDUAPEEU-SNAWJCMRSA-N 0.000 claims description 5
- VYJUETVRHRXQFA-AATRIKPKSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-[2-(trifluoromethyl)phenyl]prop-2-enamide Chemical compound FC(F)(F)C1=CC=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 VYJUETVRHRXQFA-AATRIKPKSA-N 0.000 claims description 5
- FKRVCWSLGVBIGB-VOTSOKGWSA-N (e)-n-(3-cyano-1-azabicyclo[2.2.2]octan-3-yl)-3-phenylprop-2-enamide Chemical compound C1N(CC2)CCC2C1(C#N)NC(=O)\C=C\C1=CC=CC=C1 FKRVCWSLGVBIGB-VOTSOKGWSA-N 0.000 claims description 5
- XZVQIURADIYJDK-BQYQJAHWSA-N (e)-n-(3-methyl-1-azabicyclo[2.2.2]octan-3-yl)-3-phenylprop-2-enamide Chemical compound C1N(CC2)CCC2C1(C)NC(=O)\C=C\C1=CC=CC=C1 XZVQIURADIYJDK-BQYQJAHWSA-N 0.000 claims description 5
- HSTDTPMOYSFAIB-ISUDXETCSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(1h-imidazol-5-yl)prop-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)\C=C\C1=CNC=N1 HSTDTPMOYSFAIB-ISUDXETCSA-N 0.000 claims description 5
- DXSJNKAJPNKROG-YUKKFKLSSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(5-hydroxypyridin-3-yl)prop-2-enamide Chemical compound OC1=CN=CC(\C=C\C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 DXSJNKAJPNKROG-YUKKFKLSSA-N 0.000 claims description 5
- NBTHWOKIJJBULB-FAAWYNLUSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(5-methoxypyridin-3-yl)prop-2-enamide Chemical compound COC1=CN=CC(\C=C\C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 NBTHWOKIJJBULB-FAAWYNLUSA-N 0.000 claims description 5
- MIWLXSRIICDTEX-JWPFQLSCSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(5-nitrofuran-2-yl)prop-2-enamide Chemical compound O1C([N+](=O)[O-])=CC=C1\C=C\C(=O)N[C@@H]1C(CC2)CCN2C1 MIWLXSRIICDTEX-JWPFQLSCSA-N 0.000 claims description 5
- ATNVHCFFVIVLSM-OOPCZODUSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(furan-2-yl)prop-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)\C=C\C1=CC=CO1 ATNVHCFFVIVLSM-OOPCZODUSA-N 0.000 claims description 5
- WMUJNOJUYWXQSG-AORQRIRUSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(furan-3-yl)prop-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)\C=C\C=1C=COC=1 WMUJNOJUYWXQSG-AORQRIRUSA-N 0.000 claims description 5
- QDJIWDUPQLKWAA-RGDDUWESSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-[3-(trifluoromethyl)phenyl]prop-2-enamide Chemical compound FC(F)(F)C1=CC=CC(\C=C\C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 QDJIWDUPQLKWAA-RGDDUWESSA-N 0.000 claims description 5
- NZONTOQHVFUZMV-OOPCZODUSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-thiophen-2-ylprop-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)\C=C\C1=CC=CS1 NZONTOQHVFUZMV-OOPCZODUSA-N 0.000 claims description 5
- NIJKEAAXBOXSNC-AORQRIRUSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-thiophen-3-ylprop-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)\C=C\C=1C=CSC=1 NIJKEAAXBOXSNC-AORQRIRUSA-N 0.000 claims description 5
- 208000031091 Amnestic disease Diseases 0.000 claims description 5
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims description 5
- 230000006986 amnesia Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- PHZYWNWABJJERF-NFAHFFEMSA-N (e)-3-(2-aminophenyl)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]prop-2-enamide Chemical compound NC1=CC=CC=C1\C=C\C(=O)N[C@@H]1C(CC2)CCN2C1 PHZYWNWABJJERF-NFAHFFEMSA-N 0.000 claims description 4
- HSTDTPMOYSFAIB-OWOJBTEDSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(1h-imidazol-5-yl)prop-2-enamide Chemical compound C1N(CC2)CCC2C1NC(=O)\C=C\C1=CNC=N1 HSTDTPMOYSFAIB-OWOJBTEDSA-N 0.000 claims description 4
- DWEFNEVEZVDWPJ-AATRIKPKSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(2-fluorophenyl)prop-2-enamide Chemical compound FC1=CC=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 DWEFNEVEZVDWPJ-AATRIKPKSA-N 0.000 claims description 4
- SYJFKEQPXPZQSF-ZZXKWVIFSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(4-iodophenyl)prop-2-enamide Chemical compound C1=CC(I)=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 SYJFKEQPXPZQSF-ZZXKWVIFSA-N 0.000 claims description 4
- GERXVMRTEYKZPQ-QPJJXVBHSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(4-methoxyphenyl)prop-2-enamide Chemical compound C1=CC(OC)=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 GERXVMRTEYKZPQ-QPJJXVBHSA-N 0.000 claims description 4
- DXSJNKAJPNKROG-OWOJBTEDSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(5-hydroxypyridin-3-yl)prop-2-enamide Chemical compound OC1=CN=CC(\C=C\C(=O)NC2C3CCN(CC3)C2)=C1 DXSJNKAJPNKROG-OWOJBTEDSA-N 0.000 claims description 4
- NBTHWOKIJJBULB-NSCUHMNNSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(5-methoxypyridin-3-yl)prop-2-enamide Chemical compound COC1=CN=CC(\C=C\C(=O)NC2C3CCN(CC3)C2)=C1 NBTHWOKIJJBULB-NSCUHMNNSA-N 0.000 claims description 4
- MIWLXSRIICDTEX-HNQUOIGGSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(5-nitrofuran-2-yl)prop-2-enamide Chemical compound O1C([N+](=O)[O-])=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 MIWLXSRIICDTEX-HNQUOIGGSA-N 0.000 claims description 4
- ATNVHCFFVIVLSM-ONEGZZNKSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(furan-2-yl)prop-2-enamide Chemical compound C1N(CC2)CCC2C1NC(=O)\C=C\C1=CC=CO1 ATNVHCFFVIVLSM-ONEGZZNKSA-N 0.000 claims description 4
- WMUJNOJUYWXQSG-OWOJBTEDSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(furan-3-yl)prop-2-enamide Chemical compound C1N(CC2)CCC2C1NC(=O)\C=C\C=1C=COC=1 WMUJNOJUYWXQSG-OWOJBTEDSA-N 0.000 claims description 4
- QDJIWDUPQLKWAA-SNAWJCMRSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-[3-(trifluoromethyl)phenyl]prop-2-enamide Chemical compound FC(F)(F)C1=CC=CC(\C=C\C(=O)NC2C3CCN(CC3)C2)=C1 QDJIWDUPQLKWAA-SNAWJCMRSA-N 0.000 claims description 4
- NZONTOQHVFUZMV-ONEGZZNKSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-thiophen-2-ylprop-2-enamide Chemical compound C1N(CC2)CCC2C1NC(=O)\C=C\C1=CC=CS1 NZONTOQHVFUZMV-ONEGZZNKSA-N 0.000 claims description 4
- NIJKEAAXBOXSNC-OWOJBTEDSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-thiophen-3-ylprop-2-enamide Chemical compound C1N(CC2)CCC2C1NC(=O)\C=C\C=1C=CSC=1 NIJKEAAXBOXSNC-OWOJBTEDSA-N 0.000 claims description 4
- MENCFQRKJSFDJH-GJBLVYBDSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(2-nitrophenyl)prop-2-enamide Chemical compound [O-][N+](=O)C1=CC=CC=C1\C=C\C(=O)N[C@@H]1C(CC2)CCN2C1 MENCFQRKJSFDJH-GJBLVYBDSA-N 0.000 claims description 4
- LMYLJTJHCPTSPI-VFQAQYNWSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(4-nitrophenyl)prop-2-enamide Chemical compound C1=CC([N+](=O)[O-])=CC=C1\C=C\C(=O)N[C@@H]1C(CC2)CCN2C1 LMYLJTJHCPTSPI-VFQAQYNWSA-N 0.000 claims description 4
- HVWIZNLEMLWNOA-BYIUCRAPSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-phenylbut-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)\C=C(/C)C1=CC=CC=C1 HVWIZNLEMLWNOA-BYIUCRAPSA-N 0.000 claims description 4
- HVWIZNLEMLWNOA-KVNDZABWSA-N (z)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-phenylbut-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)/C=C(/C)C1=CC=CC=C1 HVWIZNLEMLWNOA-KVNDZABWSA-N 0.000 claims description 4
- ODFSOOCVJPIZNA-XHPSBEMXSA-N (z)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-phenylprop-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)\C=C/C1=CC=CC=C1 ODFSOOCVJPIZNA-XHPSBEMXSA-N 0.000 claims description 4
- 208000026139 Memory disease Diseases 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 230000006984 memory degeneration Effects 0.000 claims description 4
- 208000023060 memory loss Diseases 0.000 claims description 4
- 239000011593 sulfur Substances 0.000 claims description 4
- FJJBZFQDEHWYCR-MEPUESOJSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2,3-diphenylprop-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(\C=1C=CC=CC=1)=C\C1=CC=CC=C1 FJJBZFQDEHWYCR-MEPUESOJSA-N 0.000 claims description 3
- LBVMWSPLUKLPOJ-BYIUCRAPSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-methyl-3-phenylprop-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(/C)=C/C1=CC=CC=C1 LBVMWSPLUKLPOJ-BYIUCRAPSA-N 0.000 claims description 3
- MFIWCTVYPBIGQT-JFDDCEBESA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(2-formamidophenyl)prop-2-enamide Chemical compound O=CNC1=CC=CC=C1\C=C\C(=O)N[C@@H]1C(CC2)CCN2C1 MFIWCTVYPBIGQT-JFDDCEBESA-N 0.000 claims description 3
- QOFOUEFCNYRQQX-OMDKTOEGSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(3,4-dichlorophenyl)prop-2-enamide Chemical compound C1=C(Cl)C(Cl)=CC=C1\C=C\C(=O)N[C@@H]1C(CC2)CCN2C1 QOFOUEFCNYRQQX-OMDKTOEGSA-N 0.000 claims description 3
- TYYMXUGFPLAOSL-RGDDUWESSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(3-bromophenyl)prop-2-enamide Chemical compound BrC1=CC=CC(\C=C\C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 TYYMXUGFPLAOSL-RGDDUWESSA-N 0.000 claims description 3
- OOZULDOHFTVWCS-RGDDUWESSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(3-chlorophenyl)prop-2-enamide Chemical compound ClC1=CC=CC(\C=C\C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 OOZULDOHFTVWCS-RGDDUWESSA-N 0.000 claims description 3
- YAUMYTQGLWXDIH-RGDDUWESSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(3-fluorophenyl)prop-2-enamide Chemical compound FC1=CC=CC(\C=C\C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 YAUMYTQGLWXDIH-RGDDUWESSA-N 0.000 claims description 3
- WHMOYHBOLPOUMR-JFDDCEBESA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(3-methoxyphenyl)prop-2-enamide Chemical compound COC1=CC=CC(\C=C\C(=O)N[C@@H]2C3CCN(CC3)C2)=C1 WHMOYHBOLPOUMR-JFDDCEBESA-N 0.000 claims description 3
- WARWHFWAFGSZMP-VFQAQYNWSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(4-bromophenyl)prop-2-enamide Chemical compound C1=CC(Br)=CC=C1\C=C\C(=O)N[C@@H]1C(CC2)CCN2C1 WARWHFWAFGSZMP-VFQAQYNWSA-N 0.000 claims description 3
- WUSJALGTATXXGB-VFQAQYNWSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(4-chlorophenyl)prop-2-enamide Chemical compound C1=CC(Cl)=CC=C1\C=C\C(=O)N[C@@H]1C(CC2)CCN2C1 WUSJALGTATXXGB-VFQAQYNWSA-N 0.000 claims description 3
- VUDAUVWKTXMSDD-GIZXNFQBSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(4-formamidophenyl)prop-2-enamide Chemical compound C1=CC(NC=O)=CC=C1\C=C\C(=O)N[C@@H]1C(CC2)CCN2C1 VUDAUVWKTXMSDD-GIZXNFQBSA-N 0.000 claims description 3
- GERXVMRTEYKZPQ-RRGWEWPQSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(4-methoxyphenyl)prop-2-enamide Chemical compound C1=CC(OC)=CC=C1\C=C\C(=O)N[C@@H]1C(CC2)CCN2C1 GERXVMRTEYKZPQ-RRGWEWPQSA-N 0.000 claims description 3
- ODFSOOCVJPIZNA-LFAOLKIESA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-phenylprop-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)\C=C\C1=CC=CC=C1 ODFSOOCVJPIZNA-LFAOLKIESA-N 0.000 claims description 3
- QPOFOAHKDBURCL-NNTXTVRGSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-pyridin-2-ylprop-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)\C=C\C1=CC=CC=N1 QPOFOAHKDBURCL-NNTXTVRGSA-N 0.000 claims description 3
- IFRBWXFNEPBBKA-XGACYXMMSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-pyridin-3-ylprop-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)\C=C\C1=CC=CN=C1 IFRBWXFNEPBBKA-XGACYXMMSA-N 0.000 claims description 3
- XELSBDUTKCSMDH-YUKKFKLSSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-pyridin-4-ylprop-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)\C=C\C1=CC=NC=C1 XELSBDUTKCSMDH-YUKKFKLSSA-N 0.000 claims description 3
- LBVMWSPLUKLPOJ-SICOMBFOSA-N (e)-n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-2-methyl-3-phenylprop-2-enamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(/C)=C/C1=CC=CC=C1 LBVMWSPLUKLPOJ-SICOMBFOSA-N 0.000 claims description 3
- MENCFQRKJSFDJH-VBROQKIQSA-N (e)-n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-3-(2-nitrophenyl)prop-2-enamide Chemical compound [O-][N+](=O)C1=CC=CC=C1\C=C\C(=O)N[C@H]1C(CC2)CCN2C1 MENCFQRKJSFDJH-VBROQKIQSA-N 0.000 claims description 3
- ODFSOOCVJPIZNA-LQYUOIDQSA-N (e)-n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-3-phenylprop-2-enamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)\C=C\C1=CC=CC=C1 ODFSOOCVJPIZNA-LQYUOIDQSA-N 0.000 claims description 3
- QODFPISBGYJKDV-SREVYHEPSA-N (z)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(2-methoxyphenyl)prop-2-enamide Chemical compound COC1=CC=CC=C1\C=C/C(=O)NC1C(CC2)CCN2C1 QODFPISBGYJKDV-SREVYHEPSA-N 0.000 claims description 3
- MGQYIEIAFOISHD-LTBFUDJGSA-N (z)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-2-fluoro-3-phenylprop-2-enamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(/F)=C/C1=CC=CC=C1 MGQYIEIAFOISHD-LTBFUDJGSA-N 0.000 claims description 3
- QODFPISBGYJKDV-XHPSBEMXSA-N (z)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(2-methoxyphenyl)prop-2-enamide Chemical compound COC1=CC=CC=C1\C=C/C(=O)N[C@@H]1C(CC2)CCN2C1 QODFPISBGYJKDV-XHPSBEMXSA-N 0.000 claims description 3
- 230000006735 deficit Effects 0.000 claims description 3
- 208000020016 psychiatric disease Diseases 0.000 claims description 3
- RCLFFPCOTKNDRK-ZZXKWVIFSA-N (e)-3-(4-aminophenyl)-n-(1-azabicyclo[2.2.2]octan-3-yl)prop-2-enamide Chemical compound C1=CC(N)=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 RCLFFPCOTKNDRK-ZZXKWVIFSA-N 0.000 claims description 2
- FJJBZFQDEHWYCR-HMMYKYKNSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-2,3-diphenylprop-2-enamide Chemical compound C1N(CC2)CCC2C1NC(=O)C(\C=1C=CC=CC=1)=C\C1=CC=CC=C1 FJJBZFQDEHWYCR-HMMYKYKNSA-N 0.000 claims description 2
- LBVMWSPLUKLPOJ-ACCUITESSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-2-methyl-3-phenylprop-2-enamide Chemical compound C1N(CC2)CCC2C1NC(=O)C(/C)=C/C1=CC=CC=C1 LBVMWSPLUKLPOJ-ACCUITESSA-N 0.000 claims description 2
- MFIWCTVYPBIGQT-AATRIKPKSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(2-formamidophenyl)prop-2-enamide Chemical compound O=CNC1=CC=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 MFIWCTVYPBIGQT-AATRIKPKSA-N 0.000 claims description 2
- QODFPISBGYJKDV-VOTSOKGWSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(2-methoxyphenyl)prop-2-enamide Chemical compound COC1=CC=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 QODFPISBGYJKDV-VOTSOKGWSA-N 0.000 claims description 2
- NVVYTUXHKCMTCD-VOTSOKGWSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(2-methylphenyl)prop-2-enamide Chemical compound CC1=CC=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 NVVYTUXHKCMTCD-VOTSOKGWSA-N 0.000 claims description 2
- TYYMXUGFPLAOSL-SNAWJCMRSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(3-bromophenyl)prop-2-enamide Chemical compound BrC1=CC=CC(\C=C\C(=O)NC2C3CCN(CC3)C2)=C1 TYYMXUGFPLAOSL-SNAWJCMRSA-N 0.000 claims description 2
- WHMOYHBOLPOUMR-AATRIKPKSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(3-methoxyphenyl)prop-2-enamide Chemical compound COC1=CC=CC(\C=C\C(=O)NC2C3CCN(CC3)C2)=C1 WHMOYHBOLPOUMR-AATRIKPKSA-N 0.000 claims description 2
- WARWHFWAFGSZMP-ZZXKWVIFSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(4-bromophenyl)prop-2-enamide Chemical compound C1=CC(Br)=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 WARWHFWAFGSZMP-ZZXKWVIFSA-N 0.000 claims description 2
- WUSJALGTATXXGB-ZZXKWVIFSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(4-chlorophenyl)prop-2-enamide Chemical compound C1=CC(Cl)=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 WUSJALGTATXXGB-ZZXKWVIFSA-N 0.000 claims description 2
- GBLPTBJUUSMWLC-ZZXKWVIFSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(4-fluorophenyl)prop-2-enamide Chemical compound C1=CC(F)=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 GBLPTBJUUSMWLC-ZZXKWVIFSA-N 0.000 claims description 2
- VUDAUVWKTXMSDD-ZZXKWVIFSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(4-formamidophenyl)prop-2-enamide Chemical compound C1=CC(NC=O)=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 VUDAUVWKTXMSDD-ZZXKWVIFSA-N 0.000 claims description 2
- LMYLJTJHCPTSPI-ZZXKWVIFSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(4-nitrophenyl)prop-2-enamide Chemical compound C1=CC([N+](=O)[O-])=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 LMYLJTJHCPTSPI-ZZXKWVIFSA-N 0.000 claims description 2
- HVWIZNLEMLWNOA-ACCUITESSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-phenylbut-2-enamide Chemical compound C1N(CC2)CCC2C1NC(=O)\C=C(/C)C1=CC=CC=C1 HVWIZNLEMLWNOA-ACCUITESSA-N 0.000 claims description 2
- QPOFOAHKDBURCL-SNAWJCMRSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-pyridin-2-ylprop-2-enamide Chemical compound C1N(CC2)CCC2C1NC(=O)\C=C\C1=CC=CC=N1 QPOFOAHKDBURCL-SNAWJCMRSA-N 0.000 claims description 2
- IFRBWXFNEPBBKA-ONEGZZNKSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-pyridin-3-ylprop-2-enamide Chemical compound C1N(CC2)CCC2C1NC(=O)\C=C\C1=CC=CN=C1 IFRBWXFNEPBBKA-ONEGZZNKSA-N 0.000 claims description 2
- XELSBDUTKCSMDH-OWOJBTEDSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-pyridin-4-ylprop-2-enamide Chemical compound C1N(CC2)CCC2C1NC(=O)\C=C\C1=CC=NC=C1 XELSBDUTKCSMDH-OWOJBTEDSA-N 0.000 claims description 2
- NVVYTUXHKCMTCD-MOEXGYKKSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(2-methylphenyl)prop-2-enamide Chemical compound CC1=CC=CC=C1\C=C\C(=O)N[C@@H]1C(CC2)CCN2C1 NVVYTUXHKCMTCD-MOEXGYKKSA-N 0.000 claims description 2
- GBLPTBJUUSMWLC-VFQAQYNWSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(4-fluorophenyl)prop-2-enamide Chemical compound C1=CC(F)=CC=C1\C=C\C(=O)N[C@@H]1C(CC2)CCN2C1 GBLPTBJUUSMWLC-VFQAQYNWSA-N 0.000 claims description 2
- NVVYTUXHKCMTCD-FYCOFBDGSA-N (e)-n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-3-(2-methylphenyl)prop-2-enamide Chemical compound CC1=CC=CC=C1\C=C\C(=O)N[C@H]1C(CC2)CCN2C1 NVVYTUXHKCMTCD-FYCOFBDGSA-N 0.000 claims description 2
- MGQYIEIAFOISHD-UVTDQMKNSA-N (z)-n-(1-azabicyclo[2.2.2]octan-3-yl)-2-fluoro-3-phenylprop-2-enamide Chemical compound C1N(CC2)CCC2C1NC(=O)C(/F)=C/C1=CC=CC=C1 MGQYIEIAFOISHD-UVTDQMKNSA-N 0.000 claims description 2
- HVWIZNLEMLWNOA-QBFSEMIESA-N (z)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-phenylbut-2-enamide Chemical compound C1N(CC2)CCC2C1NC(=O)/C=C(/C)C1=CC=CC=C1 HVWIZNLEMLWNOA-QBFSEMIESA-N 0.000 claims description 2
- ODFSOOCVJPIZNA-SREVYHEPSA-N (z)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-phenylprop-2-enamide Chemical compound C1N(CC2)CCC2C1NC(=O)\C=C/C1=CC=CC=C1 ODFSOOCVJPIZNA-SREVYHEPSA-N 0.000 claims description 2
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 206010027374 Mental impairment Diseases 0.000 claims 3
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 111
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 86
- 239000012458 free base Substances 0.000 description 44
- STZHBULOYDCZET-KLXURFKVSA-N (3r)-1-azabicyclo[2.2.2]octan-3-amine;dihydrochloride Chemical compound Cl.Cl.C1CC2[C@@H](N)CN1CC2 STZHBULOYDCZET-KLXURFKVSA-N 0.000 description 35
- 239000000203 mixture Substances 0.000 description 33
- 239000000243 solution Substances 0.000 description 30
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 28
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 21
- 238000004587 chromatography analysis Methods 0.000 description 21
- 239000000741 silica gel Substances 0.000 description 21
- 229910002027 silica gel Inorganic materials 0.000 description 21
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 20
- 239000007787 solid Substances 0.000 description 18
- 239000010410 layer Substances 0.000 description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000004007 reversed phase HPLC Methods 0.000 description 9
- 239000003643 water by type Substances 0.000 description 9
- STZHBULOYDCZET-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-amine;hydron;dichloride Chemical compound Cl.Cl.C1CC2C(N)CN1CC2 STZHBULOYDCZET-UHFFFAOYSA-N 0.000 description 8
- STZHBULOYDCZET-XCUBXKJBSA-N (3s)-1-azabicyclo[2.2.2]octan-3-amine;dihydrochloride Chemical compound Cl.Cl.C1CC2[C@H](N)CN1CC2 STZHBULOYDCZET-XCUBXKJBSA-N 0.000 description 7
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 7
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 7
- 239000003480 eluent Substances 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- BRJQKJLCLZBQCK-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octane;prop-2-enamide Chemical class NC(=O)C=C.C1CC2CCN1CC2 BRJQKJLCLZBQCK-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- AHDDRJBFJBDEPW-DTWKUNHWSA-N trans-2-Phenylcyclopropanecarboxylic acid Chemical compound OC(=O)[C@@H]1C[C@H]1C1=CC=CC=C1 AHDDRJBFJBDEPW-DTWKUNHWSA-N 0.000 description 4
- WBYWAXJHAXSJNI-VOTSOKGWSA-N trans-cinnamic acid Chemical compound OC(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-N 0.000 description 4
- BBQDLDVSEDAYAA-AATRIKPKSA-N 2-nitrocinnamic acid Chemical compound OC(=O)\C=C\C1=CC=CC=C1[N+]([O-])=O BBQDLDVSEDAYAA-AATRIKPKSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000000908 ammonium hydroxide Substances 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- XNCRUNXWPDJHGV-BQYQJAHWSA-N (e)-2-methyl-3-phenylprop-2-enoic acid Chemical compound OC(=O)C(/C)=C/C1=CC=CC=C1 XNCRUNXWPDJHGV-BQYQJAHWSA-N 0.000 description 2
- KJRRTHHNKJBVBO-AATRIKPKSA-N (e)-3-(2-chlorophenyl)prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=CC=C1Cl KJRRTHHNKJBVBO-AATRIKPKSA-N 0.000 description 2
- PEXWJYDPDXUVSV-BQYQJAHWSA-N (e)-3-phenylbut-2-enoic acid Chemical compound OC(=O)\C=C(/C)C1=CC=CC=C1 PEXWJYDPDXUVSV-BQYQJAHWSA-N 0.000 description 2
- VUVORVXMOLQFMO-ONEGZZNKSA-N (e)-3-pyridin-3-ylprop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=CN=C1 VUVORVXMOLQFMO-ONEGZZNKSA-N 0.000 description 2
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 2
- RSWBWHPZXKLUEX-VOTSOKGWSA-N 2-Methylcinnamic Acid Chemical compound CC1=CC=CC=C1\C=C\C(O)=O RSWBWHPZXKLUEX-VOTSOKGWSA-N 0.000 description 2
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000000954 anitussive effect Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 229910000085 borane Inorganic materials 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000007278 cognition impairment Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 230000007257 malfunction Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 2
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- XNERWVPQCYSMLC-UHFFFAOYSA-N phenylpropiolic acid Chemical compound OC(=O)C#CC1=CC=CC=C1 XNERWVPQCYSMLC-UHFFFAOYSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 230000005062 synaptic transmission Effects 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- KVYQKWPZQKGICY-UHFFFAOYSA-N (8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl)azanium;dichloride Chemical compound [Cl-].[Cl-].C1C([NH3+])CC2CCC1[NH+]2C KVYQKWPZQKGICY-UHFFFAOYSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- AMVYAIXPAGBXOM-AATRIKPKSA-N (E)-2-(trifluoromethyl)cinnamic acid Chemical compound OC(=O)\C=C\C1=CC=CC=C1C(F)(F)F AMVYAIXPAGBXOM-AATRIKPKSA-N 0.000 description 1
- FEGVSPGUHMGGBO-VOTSOKGWSA-N (E)-2-methoxycinnamic acid Chemical compound COC1=CC=CC=C1\C=C\C(O)=O FEGVSPGUHMGGBO-VOTSOKGWSA-N 0.000 description 1
- AFDXODALSZRGIH-QPJJXVBHSA-N (E)-3-(4-methoxyphenyl)prop-2-enoic acid Chemical compound COC1=CC=C(\C=C\C(O)=O)C=C1 AFDXODALSZRGIH-QPJJXVBHSA-N 0.000 description 1
- KSBWHDDGWSYETA-SNAWJCMRSA-N (E)-3-(trifluoromethyl)cinnamic acid Chemical compound OC(=O)\C=C\C1=CC=CC(C(F)(F)F)=C1 KSBWHDDGWSYETA-SNAWJCMRSA-N 0.000 description 1
- IOUDZAFBPDDAMK-AATRIKPKSA-N (e)-3-(2-fluorophenyl)prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=CC=C1F IOUDZAFBPDDAMK-AATRIKPKSA-N 0.000 description 1
- RRLUFPHCTSFKNR-DUXPYHPUSA-N (e)-3-(3,4-dichlorophenyl)prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=C(Cl)C(Cl)=C1 RRLUFPHCTSFKNR-DUXPYHPUSA-N 0.000 description 1
- YEMUSDCFQUBPAL-SNAWJCMRSA-N (e)-3-(3-bromophenyl)prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=CC(Br)=C1 YEMUSDCFQUBPAL-SNAWJCMRSA-N 0.000 description 1
- FFKGOJWPSXRALK-SNAWJCMRSA-N (e)-3-(3-chlorophenyl)prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=CC(Cl)=C1 FFKGOJWPSXRALK-SNAWJCMRSA-N 0.000 description 1
- RTSIUKMGSDOSTI-SNAWJCMRSA-N (e)-3-(3-fluorophenyl)prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=CC(F)=C1 RTSIUKMGSDOSTI-SNAWJCMRSA-N 0.000 description 1
- XQOFQTFBKOHMCW-SNAWJCMRSA-N (e)-3-(3-iodophenyl)prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=CC(I)=C1 XQOFQTFBKOHMCW-SNAWJCMRSA-N 0.000 description 1
- CPDDDTNAMBSPRN-ZZXKWVIFSA-N (e)-3-(4-bromophenyl)prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=C(Br)C=C1 CPDDDTNAMBSPRN-ZZXKWVIFSA-N 0.000 description 1
- NIDLJAPEZBFHGP-ZZXKWVIFSA-N (e)-3-(4-iodophenyl)prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=C(I)C=C1 NIDLJAPEZBFHGP-ZZXKWVIFSA-N 0.000 description 1
- IENCUXURMYOKEK-OWOJBTEDSA-N (e)-3-(5-hydroxypyridin-3-yl)prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CN=CC(O)=C1 IENCUXURMYOKEK-OWOJBTEDSA-N 0.000 description 1
- MSXLMJSPKJQXBE-NSCUHMNNSA-N (e)-3-(5-methoxypyridin-3-yl)prop-2-enoic acid Chemical compound COC1=CN=CC(\C=C\C(O)=O)=C1 MSXLMJSPKJQXBE-NSCUHMNNSA-N 0.000 description 1
- ZCJLOOJRNPHKAV-ONEGZZNKSA-N (e)-3-(furan-2-yl)prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=CO1 ZCJLOOJRNPHKAV-ONEGZZNKSA-N 0.000 description 1
- JHAPZUDWRRBZHZ-OWOJBTEDSA-N (e)-3-(furan-3-yl)prop-2-enoic acid Chemical compound OC(=O)\C=C\C=1C=COC=1 JHAPZUDWRRBZHZ-OWOJBTEDSA-N 0.000 description 1
- ZWKNLRXFUTWSOY-QPJJXVBHSA-N (e)-3-phenylprop-2-enenitrile Chemical compound N#C\C=C\C1=CC=CC=C1 ZWKNLRXFUTWSOY-QPJJXVBHSA-N 0.000 description 1
- WOGITNXCNOTRLK-VOTSOKGWSA-N (e)-3-phenylprop-2-enoyl chloride Chemical compound ClC(=O)\C=C\C1=CC=CC=C1 WOGITNXCNOTRLK-VOTSOKGWSA-N 0.000 description 1
- LKDFTXDJKHGCAC-SNAWJCMRSA-N (e)-3-pyridin-2-ylprop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=CC=N1 LKDFTXDJKHGCAC-SNAWJCMRSA-N 0.000 description 1
- VYRYYUKILKRGDN-OWOJBTEDSA-N (e)-3-thiophen-3-ylprop-2-enoic acid Chemical compound OC(=O)\C=C\C=1C=CSC=1 VYRYYUKILKRGDN-OWOJBTEDSA-N 0.000 description 1
- QOFOUEFCNYRQQX-DUXPYHPUSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(3,4-dichlorophenyl)prop-2-enamide Chemical compound C1=C(Cl)C(Cl)=CC=C1\C=C\C(=O)NC1C(CC2)CCN2C1 QOFOUEFCNYRQQX-DUXPYHPUSA-N 0.000 description 1
- OOZULDOHFTVWCS-SNAWJCMRSA-N (e)-n-(1-azabicyclo[2.2.2]octan-3-yl)-3-(3-chlorophenyl)prop-2-enamide Chemical compound ClC1=CC=CC(\C=C\C(=O)NC2C3CCN(CC3)C2)=C1 OOZULDOHFTVWCS-SNAWJCMRSA-N 0.000 description 1
- JEZKVTBNTCBZAF-NFAHFFEMSA-N (e)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-3-(2-chlorophenyl)prop-2-enamide Chemical compound ClC1=CC=CC=C1\C=C\C(=O)N[C@@H]1C(CC2)CCN2C1 JEZKVTBNTCBZAF-NFAHFFEMSA-N 0.000 description 1
- JEZKVTBNTCBZAF-LLYBFZRZSA-N (e)-n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-3-(2-chlorophenyl)prop-2-enamide Chemical compound ClC1=CC=CC=C1\C=C\C(=O)N[C@H]1C(CC2)CCN2C1 JEZKVTBNTCBZAF-LLYBFZRZSA-N 0.000 description 1
- QONCEXMULRJPPY-VURMDHGXSA-N (z)-2-fluoro-3-phenylprop-2-enoic acid Chemical compound OC(=O)C(\F)=C\C1=CC=CC=C1 QONCEXMULRJPPY-VURMDHGXSA-N 0.000 description 1
- FEGVSPGUHMGGBO-SREVYHEPSA-N (z)-3-(2-methoxyphenyl)prop-2-enoic acid Chemical compound COC1=CC=CC=C1\C=C/C(O)=O FEGVSPGUHMGGBO-SREVYHEPSA-N 0.000 description 1
- PEXWJYDPDXUVSV-FPLPWBNLSA-N (z)-3-phenylbut-2-enoic acid Chemical compound OC(=O)/C=C(/C)C1=CC=CC=C1 PEXWJYDPDXUVSV-FPLPWBNLSA-N 0.000 description 1
- KKMZQOIASVGJQE-ONEGZZNKSA-N 2-Thiopheneacrylic acid Chemical compound OC(=O)\C=C\C1=CC=CS1 KKMZQOIASVGJQE-ONEGZZNKSA-N 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- LWOWNIPZHGWKNR-DUXPYHPUSA-N 3-(5-nitro-2-furyl)acrylic acid Chemical compound OC(=O)\C=C\C1=CC=C([N+]([O-])=O)O1 LWOWNIPZHGWKNR-DUXPYHPUSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- LZPNXAULYJPXEH-AATRIKPKSA-N 3-Methoxycinnamic acid Chemical compound COC1=CC=CC(\C=C\C(O)=O)=C1 LZPNXAULYJPXEH-AATRIKPKSA-N 0.000 description 1
- IEWKLMGEIQEKBG-UHFFFAOYSA-N 3-methyl-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C1CC2C(C)(O)CN1CC2 IEWKLMGEIQEKBG-UHFFFAOYSA-N 0.000 description 1
- UGNSMKDDFAUGFT-UHFFFAOYSA-N 4,4-dimethyl-2-phenyl-5h-1,3-oxazole Chemical compound CC1(C)COC(C=2C=CC=CC=2)=N1 UGNSMKDDFAUGFT-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- ISMMYAZSUSYVQG-ZZXKWVIFSA-N 4-Fluorocinnamic acid Chemical compound OC(=O)\C=C\C1=CC=C(F)C=C1 ISMMYAZSUSYVQG-ZZXKWVIFSA-N 0.000 description 1
- GXLIFJYFGMHYDY-ZZXKWVIFSA-N 4-chlorocinnamic acid Chemical compound OC(=O)\C=C\C1=CC=C(Cl)C=C1 GXLIFJYFGMHYDY-ZZXKWVIFSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- XMMRNCHTDONGRJ-ZZXKWVIFSA-N 4-nitrocinnamic acid Chemical compound OC(=O)\C=C\C1=CC=C([N+]([O-])=O)C=C1 XMMRNCHTDONGRJ-ZZXKWVIFSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000006949 cholinergic function Effects 0.000 description 1
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- JASMWYNKLTULAN-UHFFFAOYSA-N octan-3-amine Chemical compound CCCCCC(N)CC JASMWYNKLTULAN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003385 sodium Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- LOIYMIARKYCTBW-OWOJBTEDSA-N trans-urocanic acid Chemical compound OC(=O)\C=C\C1=CNC=N1 LOIYMIARKYCTBW-OWOJBTEDSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- BIDDLDNGQCUOJQ-SDNWHVSQSA-N α-phenylcinnamic acid Chemical compound C=1C=CC=CC=1/C(C(=O)O)=C\C1=CC=CC=C1 BIDDLDNGQCUOJQ-SDNWHVSQSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9904176A SE9904176D0 (sv) | 1999-11-18 | 1999-11-18 | New use |
| SE9904176 | 1999-11-18 | ||
| PCT/SE2000/002262 WO2001036417A1 (en) | 1999-11-18 | 2000-11-16 | New use and novel n-azabicyclo-amide derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60020994D1 DE60020994D1 (de) | 2005-07-28 |
| DE60020994T2 true DE60020994T2 (de) | 2006-04-27 |
Family
ID=20417766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60020994T Expired - Fee Related DE60020994T2 (de) | 1999-11-18 | 2000-11-16 | Neue verwendung sowie neue n-azabicycloamid-verbindungen |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US6683090B1 (OSRAM) |
| EP (1) | EP1233964B1 (OSRAM) |
| JP (1) | JP2003514818A (OSRAM) |
| KR (1) | KR20020058014A (OSRAM) |
| CN (1) | CN1217943C (OSRAM) |
| AR (1) | AR031680A1 (OSRAM) |
| AT (1) | ATE298337T1 (OSRAM) |
| AU (1) | AU784400B2 (OSRAM) |
| BG (1) | BG106680A (OSRAM) |
| BR (1) | BR0015624A (OSRAM) |
| CA (1) | CA2389604A1 (OSRAM) |
| CO (1) | CO5261607A1 (OSRAM) |
| CZ (1) | CZ20021692A3 (OSRAM) |
| DE (1) | DE60020994T2 (OSRAM) |
| DK (1) | DK1233964T3 (OSRAM) |
| EE (1) | EE200200251A (OSRAM) |
| ES (1) | ES2242653T3 (OSRAM) |
| HU (1) | HUP0204245A3 (OSRAM) |
| IL (1) | IL149374A0 (OSRAM) |
| IS (1) | IS6385A (OSRAM) |
| MX (1) | MXPA02004911A (OSRAM) |
| NO (1) | NO20022289L (OSRAM) |
| NZ (1) | NZ518571A (OSRAM) |
| PL (1) | PL355867A1 (OSRAM) |
| PT (1) | PT1233964E (OSRAM) |
| SE (1) | SE9904176D0 (OSRAM) |
| SK (1) | SK6772002A3 (OSRAM) |
| UA (1) | UA74172C2 (OSRAM) |
| WO (1) | WO2001036417A1 (OSRAM) |
| ZA (1) | ZA200203316B (OSRAM) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7214686B2 (en) | 1997-06-30 | 2007-05-08 | Targacept, Inc. | Pharmaceutical compositions and methods for effecting dopamine release |
| SE0000540D0 (sv) | 2000-02-18 | 2000-02-18 | Astrazeneca Ab | New compounds |
| US6492386B2 (en) * | 2000-08-18 | 2002-12-10 | Pharmacia & Upjohn Company | Quinuclidine-substituted aryl compounds for treatment of disease |
| US6492385B2 (en) | 2000-08-18 | 2002-12-10 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
| US6486172B2 (en) | 2000-08-18 | 2002-11-26 | Pharmacia & Upjohn Company | Quinuclidine-substituted aryl compounds for treatment of disease |
| US6479510B2 (en) | 2000-08-18 | 2002-11-12 | Pharmacia & Upjohn Company | Quinuclidine-substituted aryl compounds for treatment of disease |
| WO2002015662A2 (en) * | 2000-08-21 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists |
| WO2002017358A2 (en) * | 2000-08-21 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists) |
| JP2004506734A (ja) * | 2000-08-21 | 2004-03-04 | ファルマシア・アンド・アップジョン・カンパニー | 疾患治療用のキヌクリド置換ヘテロアリール部分 |
| PE20021019A1 (es) | 2001-04-19 | 2002-11-13 | Upjohn Co | Grupos azabiciclicos sustituidos |
| AR036041A1 (es) | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen |
| AR036040A1 (es) | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen |
| NZ529880A (en) * | 2001-07-06 | 2005-09-30 | Neurosearch As | Novel compounds, their preparation and use |
| EP1419161A1 (en) | 2001-08-24 | 2004-05-19 | PHARMACIA & UPJOHN COMPANY | Substituted-heteroaryl-7-aza 2.2.1]bicycloheptanes for the treatment of disease |
| NZ531786A (en) | 2001-10-02 | 2006-10-27 | Upjohn Co | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease |
| WO2003032897A2 (en) * | 2001-10-16 | 2003-04-24 | Astrazeneca Ab | Azabicyclic compounds for the treatment of fibromyalgia syndrome |
| CA2464194A1 (en) * | 2001-10-26 | 2003-05-08 | Pharmacia & Upjohn Company | N-azabicyclo-substituted hetero-bicyclic carboxamides as nachr agonists |
| US6849620B2 (en) | 2001-10-26 | 2005-02-01 | Pfizer Inc | N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease |
| CA2466375A1 (en) | 2001-11-08 | 2003-05-15 | Pharmacia & Upjohn Company | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease |
| BR0214016A (pt) | 2001-11-09 | 2004-10-13 | Upjohn Co | Compostos azabicìclico-fenil-fundido heterocìclicos e seu uso como ligandos alfa 7 nachr |
| US7067261B2 (en) | 2001-12-14 | 2006-06-27 | Targacept, Inc. | Methods and compositions for treatment of central nervous system disorders |
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| AU2003210730A1 (en) | 2002-02-15 | 2003-09-09 | Pharmacia And Upjohn Company | Azabicyclo-substituted benzoylamides and thioamides for treatment of cns-related disorders |
| MXPA04008152A (es) | 2002-02-19 | 2005-09-08 | Upjohn Co | Compuestos azabiciclicos para el tratamiento de enfermedades. |
| AU2003219690A1 (en) | 2002-02-19 | 2003-09-09 | Pharmacia And Upjohn Company | Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease |
| CN1656093A (zh) | 2002-05-30 | 2005-08-17 | 神经研究公司 | 3－取代的奎宁环及其用途 |
| US7176198B2 (en) | 2002-08-01 | 2007-02-13 | Pfizer Inc. | 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease |
| US7244745B2 (en) | 2002-08-30 | 2007-07-17 | Memory Pharmaceuticals Corp. | Heterocyclic compounds, methods for the preparation thereof, and uses thereof |
| GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
| ES2405594T3 (es) | 2002-09-25 | 2013-05-31 | Memory Pharmaceuticals Corporation | Idazoles, benzotiazoles y benzisotiazoles, y preparación y usos de los mismos |
| JP2006510662A (ja) * | 2002-12-11 | 2006-03-30 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | α７ニコチン性アセチルコリン受容体アゴニストとその他の化合物との組合せによる疾患の治療 |
| EP1678172B1 (en) | 2003-10-15 | 2009-12-09 | Targacept, Inc. | Azabicyclic compounds for relieving pain and treating central nervous system disorders |
| BRPI0508771A (pt) | 2004-03-25 | 2007-08-14 | Memory Pharm Corp | indazóis, benzotiazóis, benzoisotiazóis, benzisoxazóis, e a preparação e usos dos mesmos |
| PE20060437A1 (es) | 2004-06-18 | 2006-06-08 | Novartis Ag | COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR |
| GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
| CN101248073A (zh) | 2005-08-22 | 2008-08-20 | 塔加西普特公司 | 杂芳基-取代的二氮杂三环烷类、其制备方法及其应用 |
| JP5109132B2 (ja) * | 2005-09-28 | 2012-12-26 | 国立大学法人 熊本大学 | 注意欠陥・多動性障害の治療薬 |
| GB0521508D0 (en) | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
| GB0525672D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| GB0525673D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| WO2008008884A2 (en) * | 2006-07-12 | 2008-01-17 | Cornell Research Foundation, Inc. | Inhibition of beta-amyloid peptide aggregation |
| CL2008000119A1 (es) | 2007-01-16 | 2008-05-16 | Wyeth Corp | Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia. |
| SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
| ATE503754T1 (de) | 2007-10-01 | 2011-04-15 | Comentis Inc | 1h-indol-3-carbonsäure-chinuclidin-4- ylmethylesterderivate als liganden für den nikotinischen alpha-7-acetylcholinrezeptor zur behandlung von alzheimer-krankheit |
| KR20100113163A (ko) | 2008-02-13 | 2010-10-20 | 타가셉트 인코포레이티드 | 알파 ７ 니코틴 작용제 및 항정신병제의 조합 |
| TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
| CN103221411B (zh) | 2010-05-17 | 2016-05-11 | 富瑞姆制药公司 | (R)-7-氯-N-(奎宁环-3-基)苯并[b]噻吩-2-甲酰胺盐酸盐单水合物的晶型 |
| FR2974365B1 (fr) * | 2011-04-20 | 2017-08-25 | Centre Nat De La Rech Scient (C N R S) | 1,2,3-triazoles 1,4-disubstituees, leurs procedes de preparation et leurs utilisations diagnostiques et therapeutiques |
| WO2012177856A2 (en) * | 2011-06-21 | 2012-12-27 | Adispell, Inc. | Cognition modification |
| GB201111704D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Novel compounds |
| GB201111705D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Compounds and their use |
| JO3115B1 (ar) | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
| CA2872005A1 (en) | 2012-05-08 | 2013-11-14 | Forum Pharmaceuticals, Inc. | Methods of maintaining, treating or improving cognitive function |
| GB201209587D0 (en) | 2012-05-30 | 2012-07-11 | Takeda Pharmaceutical | Therapeutic compounds |
| ES2694299T3 (es) | 2013-02-07 | 2018-12-19 | Heptares Therapeutics Limited | Carboxilatos de piperidin-1-ilo y azepin-1-ilo como agonistas del receptor muscarínico M4 |
| EA029430B1 (ru) | 2013-06-21 | 2018-03-30 | Такеда Фармасьютикл Компани Лимитед | Производные 1-сульфонилпиперидина в качестве модуляторов рецепторов прокинетицина |
| GB201314286D0 (en) | 2013-08-08 | 2013-09-25 | Takeda Pharmaceutical | Therapeutic Compounds |
| GB201318222D0 (en) | 2013-10-15 | 2013-11-27 | Takeda Pharmaceutical | Novel compounds |
| GB201320905D0 (en) | 2013-11-27 | 2014-01-08 | Takeda Pharmaceutical | Therapeutic compounds |
| TW201613864A (en) | 2014-02-20 | 2016-04-16 | Takeda Pharmaceutical | Novel compounds |
| TW201617342A (zh) | 2014-07-11 | 2016-05-16 | 阿法馬根公司 | 調節α７活性之啶類 |
| US9724340B2 (en) | 2015-07-31 | 2017-08-08 | Attenua, Inc. | Antitussive compositions and methods |
| GB201616839D0 (en) | 2016-10-04 | 2016-11-16 | Takeda Pharmaceutical Company Limited | Therapeutic compounds |
| GB201619514D0 (en) | 2016-11-18 | 2017-01-04 | Takeda Pharmaceuticals Co | Novel compounds |
| JP2021138648A (ja) | 2020-03-04 | 2021-09-16 | 武田薬品工業株式会社 | 経口固形製剤 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1255467B (it) | 1992-07-29 | 1995-11-02 | Dompe Farmaceutici Spa | Ammidi acriliche farmacologicamente attive |
| GB9304500D0 (en) | 1993-03-05 | 1993-04-21 | Glaxo Spa | Heterocyclic compounds |
| CZ217697A3 (cs) * | 1995-01-10 | 1998-03-18 | Smithkline Beecham S. P. A. | Indolové deriváty, kterých je možno použít pro léčení osteoporózy, způsob jejich přípravy, farmaceutický prostředek obsahující tyto deriváty a použití |
-
1999
- 1999-11-18 SE SE9904176A patent/SE9904176D0/xx unknown
-
2000
- 2000-11-06 AR ARP000105840A patent/AR031680A1/es not_active Application Discontinuation
- 2000-11-16 EE EEP200200251A patent/EE200200251A/xx unknown
- 2000-11-16 DE DE60020994T patent/DE60020994T2/de not_active Expired - Fee Related
- 2000-11-16 DK DK00981994T patent/DK1233964T3/da active
- 2000-11-16 CA CA002389604A patent/CA2389604A1/en not_active Abandoned
- 2000-11-16 PL PL00355867A patent/PL355867A1/xx not_active Application Discontinuation
- 2000-11-16 CZ CZ20021692A patent/CZ20021692A3/cs unknown
- 2000-11-16 JP JP2001538906A patent/JP2003514818A/ja active Pending
- 2000-11-16 BR BR0015624-8A patent/BR0015624A/pt not_active IP Right Cessation
- 2000-11-16 AT AT00981994T patent/ATE298337T1/de not_active IP Right Cessation
- 2000-11-16 CN CN008184216A patent/CN1217943C/zh not_active Expired - Fee Related
- 2000-11-16 EP EP00981994A patent/EP1233964B1/en not_active Expired - Lifetime
- 2000-11-16 US US10/130,635 patent/US6683090B1/en not_active Expired - Fee Related
- 2000-11-16 KR KR1020027006257A patent/KR20020058014A/ko not_active Ceased
- 2000-11-16 AU AU19073/01A patent/AU784400B2/en not_active Ceased
- 2000-11-16 NZ NZ518571A patent/NZ518571A/en unknown
- 2000-11-16 PT PT00981994T patent/PT1233964E/pt unknown
- 2000-11-16 WO PCT/SE2000/002262 patent/WO2001036417A1/en not_active Ceased
- 2000-11-16 UA UA2002065003A patent/UA74172C2/uk unknown
- 2000-11-16 SK SK677-2002A patent/SK6772002A3/sk unknown
- 2000-11-16 HU HU0204245A patent/HUP0204245A3/hu unknown
- 2000-11-16 MX MXPA02004911A patent/MXPA02004911A/es active IP Right Grant
- 2000-11-16 ES ES00981994T patent/ES2242653T3/es not_active Expired - Lifetime
- 2000-11-16 IL IL14937400A patent/IL149374A0/xx unknown
- 2000-11-17 CO CO00087729A patent/CO5261607A1/es not_active Application Discontinuation
-
2002
- 2002-04-25 ZA ZA200203316A patent/ZA200203316B/xx unknown
- 2002-05-09 BG BG106680A patent/BG106680A/bg unknown
- 2002-05-14 NO NO20022289A patent/NO20022289L/no unknown
- 2002-05-15 IS IS6385A patent/IS6385A/is unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60020994T2 (de) | Neue verwendung sowie neue n-azabicycloamid-verbindungen | |
| DE60100996T2 (de) | Biarylcarboxamide | |
| DE60005054T2 (de) | Chinuclidin-acrylamide | |
| DE69333143T2 (de) | Substituierte chinuclidine als substanz p antagonisten | |
| EP1448530B1 (de) | Heteroarylcarbonsäureamide | |
| DE69713295T2 (de) | Azabicyclishe carbaniumsaureester zur therapeutsichen verwendung | |
| EP1461335B1 (de) | 2-heteroarylcarbonsäureamide | |
| DE69232334T2 (de) | Substituierte 3-aminochinuclidine | |
| DE69329386T2 (de) | Substituierte benzylaminoquinuclidine als substanz p antagonisten | |
| EP1487834B1 (de) | Aza-bicyclische n-biarylamide mit affinität zum alpha7 nikotinischen acetylcholin-rezeptor | |
| DE69208877T2 (de) | Chinuclidinderivate | |
| DE60311853T2 (de) | Neue 1,4-diazabicycloalkanderivate, deren herstellung und verwendung | |
| DE69908185T2 (de) | Therapeutisch nützliche arylalkylamine von spirofuropyridinen | |
| DE69735891T2 (de) | Pyridon-kondensierte azabicyclische- oder cytisinderivate, ihre herstellung und verwendung in der suchttherapie | |
| DE3877470T2 (de) | Oxazole und thiazole zur behandlung seniler demenz. | |
| EP0458214A1 (de) | Bicyclische 1-Aza-cycloalkane | |
| DE10162375A1 (de) | Bicyclische N-Aryl-amide | |
| DE2411382B2 (de) | 2-Tetrahydrofurfuryl-6,7-benzomorphane, Verfahren zur Herstellung und deren Verwendung | |
| CH626344A5 (OSRAM) | ||
| DD300105A5 (de) | Neue R(-)3-Quinuliclidinol - Derivate | |
| EP1651645B1 (de) | N-biarylamide | |
| EP0770082A1 (de) | Dioxo-thiopyrano-pyridin-carbonsäure-derivate und ihre verwendung als arzneimittel | |
| DE10162442A1 (de) | Monocyclische N-Aryl-amide | |
| DE69802624T2 (de) | Tetrahydroimidazo[2,1-a]isochinolinderivate | |
| AT395852B (de) | Imidazolyl-methyl-tetrahydrothiophenderivate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |